Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press1710.17650/2222-8721-2014-0-2-6-15LECTURES AND REVIEWSЛЕКЦИИ И ОБЗОРЫAntibodies to autoantigen targets in myasthenia and their value in clinical practiceАнтитела к аутоантигенным мишеням при миастении и их значение в клинической практикеDedaevS. I.ДедаевС. И.
Russian Federation
ordinatornevro@mail.ruMoscow Myasthenia CenterМосковский миастенический центр19062014426151902201519022015Copyright ©; 2014, Dedaev S.I.Copyright ©; 2014, Дедаев С.И.2014Dedaev S.I.Дедаев С.И.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/17

Myasthenia gravis is a classic autoimmune disease, which clinical manifestations in the form of weakness and abnormal muscle fatigue, due to the damaging effect of polyclonal antibodies to different structures of the neuromuscular synapse and muscles. The study of autoimmune substrate with myasthenia is routine in many clinics dealing with the problems of neuromuscular pathology, and the identification of high concentration of serum antibodies to a number of antigenic structures is the gold standard in diagnosis.Determination of serum antibodies to various autoimmune targets is an important tool in clinical practice. The majority of patients shows the high concentration of antibodies to AchR that gives the opportunity to use it as an important diagnostic criterion. The specificity of changes in the concentration of AchR-antibodies due to pathogenetic treatment allows to objectify the suppression of autoimmune aggression and evaluate the reliability of remission. However, the absence of AchR-antibodies when there are clear clinical and electromyography signs of myasthenia gravis suggests an autoimmune attack against a number of other targets, the most studied of which is the MuSK. On the contrary, patients with myasthenia gravis associated with thymoma, almost always have a higher level of AchR-antibodies. The presence of thymoma is accompanied by the generation of antibodies to titin and RyR, which is also observed in persons with late-onset myasthenia without thymoma. High concentration of antibodies to these structures can be interpreted as a reliable sign of thymoma in patients younger than 60 years.

myasthenia gravisantibodiesAchRMusKtitinRyRмиастенияантителаацетилхолиновые рецепторымышечная специфическая тирозинкиназатитинрианодиновые рецепторы1. Lennon V. A., Ermilov L. G., Szurszewski J. H., Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003;111:907–13.Lennon V. A., Ermilov L. G., Szurszewski J. H., Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003;111:907–13.2. Ragheb S., Mohamed M., Lisak R. P. Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the epsilon-subunit of the acetylcholine receptor. J Neuroimmunol 2005;159(1–2): 137–45.Ragheb S., Mohamed M., Lisak R. P. Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the epsilon-subunit of the acetylcholine receptor. J Neuroimmunol 2005;159(1–2): 137–45.3. Oda K. Differences in acetylcholine receptor – antibody interaction between extraocular and extremity muscle fibers. In: Myasthenia gravis and related disorders. Experimental and clinical aspects. Ann N Y Acad Sci 1993;681:238–55.Oda K. Differences in acetylcholine receptor – antibody interaction between extraocular and extremity muscle fibers. In: Myasthenia gravis and related disorders. Experimental and clinical aspects. Ann N Y Acad Sci 1993;681:238–55.4. Санадзе А. Г. Миастения и миастенические синдромы: руководство. М.: Литтера, 2012. 256 с.Санадзе А. Г. Миастения и миастенические синдромы: руководство. М.: Литтера, 2012. 256 с.5. Lindstrom J. Antibody specificities in autoimmune myasthenia gravis. Neuromuscular Diseases. N. Y., 1984. P. 481–495.Lindstrom J. Antibody specificities in autoimmune myasthenia gravis. Neuromuscular Diseases. N. Y., 1984. P. 481–495.6. Birmanns B., Brenner T., Abramsky O., Steiner I. Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. J Neurol Sci 1991;102(2):184–9.Birmanns B., Brenner T., Abramsky O., Steiner I. Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. J Neurol Sci 1991;102(2):184–9.7. Lennon V. A. Serological diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Handbook of Myasthenia gravis. R. Lisak, ed., Marcel Dekker, 1994;7. P. 149–164.Lennon V. A. Serological diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Handbook of Myasthenia gravis. R. Lisak, ed., Marcel Dekker, 1994;7. P. 149–164.8. Kawanami S., Mori S., Ueda H. Homology between Fas and nicotinic acetylcholine receptor protein in a thymoma with myasthenia gravis-immunohistochemical and biochemical study. Fukuoka Idaku Zasshi 2000;91(5):123–31.Kawanami S., Mori S., Ueda H. Homology between Fas and nicotinic acetylcholine receptor protein in a thymoma with myasthenia gravis-immunohistochemical and biochemical study. Fukuoka Idaku Zasshi 2000;91(5):123–31.9. Lennon V. A., Seybold M. E., Lindstrom J. M. et al. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978;147:973–83.Lennon V. A., Seybold M. E., Lindstrom J. M. et al. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978;147:973–83.10. Drachman D. B., Adams R. N., Josifek L. F. et al. Antibody-mediated mechanisms of ACh receptor loss in myasthenia gravis: clinical relevance. Ann N Y Acad Sci 1981;377:175–88.Drachman D. B., Adams R. N., Josifek L. F. et al. Antibody-mediated mechanisms of ACh receptor loss in myasthenia gravis: clinical relevance. Ann N Y Acad Sci 1981;377:175–88.11. Vincent A., Newson-Davis J. Antiacetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1980;43:590–600.Vincent A., Newson-Davis J. Antiacetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1980;43:590–600.12. Conti-Fine B. M., Milani M., Kaminski H. J. Myasthenia gravis: past, present, and future. J Clin InvestConti-Fine B. M., Milani M., Kaminski H. J. Myasthenia gravis: past, present, and future. J Clin Invest2006;116:2843–54.;116:2843–54.13. Поздняков О. М., Бабакова Л. Л. Пластичность нервно-мышечного синапса в патологии. Журн невропатол и психиатр им. С. С. Корсакова 1998;98(3):50–3.Поздняков О. М., Бабакова Л. Л. Пластичность нервно-мышечного синапса в патологии. Журн невропатол и психиатр им. С. С. Корсакова 1998;98(3):50–3.14. Ланцова В. Б., Сепп Е. К. Применение метода иммуноблоттинга для дифференциальной диагностики различных форм миастении и эндокринной офтальмопатии Журн экспер биол и мед 2005;140 (10):478–80.Ланцова В. Б., Сепп Е. К. Применение метода иммуноблоттинга для дифференциальной диагностики различных форм миастении и эндокринной офтальмопатии Журн экспер биол и мед 2005;140 (10):478–80.15. Aurangzeb S., Tariq M., Badshah M., Khan R. S. Relationship between antiacetylcholine receptor antibody titres and severity of myasthenia gravis. J Pak Med Assoc 2009;59(5):289–92.Aurangzeb S., Tariq M., Badshah M., Khan R. S. Relationship between antiacetylcholine receptor antibody titres and severity of myasthenia gravis. J Pak Med Assoc 2009;59(5):289–92.16. Wang W. W., Hao H. J., Gao F. Detection of multiple antibodies in myasthenia gravis and its clinical significance. Chin Med J (Engl) 2010;123(18):2555–8.Wang W. W., Hao H. J., Gao F. Detection of multiple antibodies in myasthenia gravis and its clinical significance. Chin Med J (Engl) 2010;123(18):2555–8.17. Kuks J. B., Oosterhuis H. J., Limburg P. C., The T. H. Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 1991;4(2):197–211.Kuks J. B., Oosterhuis H. J., Limburg P. C., The T. H. Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 1991;4(2):197–211.18. Дедаев С.И. Значение антител к ацетилхолиновым рецепторам в оценке эффективности лечения больных миастенией. Автореф. дис. ... канд. мед. наук. М., 2012. 25 с.Дедаев С.И. Значение антител к ацетилхолиновым рецепторам в оценке эффективности лечения больных миастенией. Автореф. дис. ... канд. мед. наук. М., 2012. 25 с.19. Glass D. J., Yancopoulos G. D. Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation. Curr Opin Neurobiol 1997;7(3):379–84.Glass D. J., Yancopoulos G. D. Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation. Curr Opin Neurobiol 1997;7(3):379–84.20. Hoch W., McConville J., Helms S. et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7(3):365–8.Hoch W., McConville J., Helms S. et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7(3):365–8.21. Щербакова Н. И., Санадзе А. Г., Сиднев Д. В., Рудниченко В. А. Клинические и электромиографические особенности серонегативной миастении. Журн неврол и психиатр им. С. С. Корсакова 2007;102(1):51–3.Щербакова Н. И., Санадзе А. Г., Сиднев Д. В., Рудниченко В. А. Клинические и электромиографические особенности серонегативной миастении. Журн неврол и психиатр им. С. С. Корсакова 2007;102(1):51–3.22. Shigemoto К., Kubo S., Maruyama N. et al. Induction of myasthenia by immunization against muscle specific kinase. J Clin Invest 2006;116(4):1016–24.Shigemoto К., Kubo S., Maruyama N. et al. Induction of myasthenia by immunization against muscle specific kinase. J Clin Invest 2006;116(4):1016–24.23. Lavrnic D., Losen M., Vujic A. et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005;76:1099–102.Lavrnic D., Losen M., Vujic A. et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005;76:1099–102.24. Selcen D., Fukuda T., Shen X. M., Engel A. G. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62(11):1945–50.Selcen D., Fukuda T., Shen X. M., Engel A. G. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62(11):1945–50.25. Bartoccioni E., Scuderi F., Minicuci G. M. et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006;67(3):505–7.Bartoccioni E., Scuderi F., Minicuci G. M. et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006;67(3):505–7.26. Scuderi F., Marino M., Colonna L. et al. Anti-p110 autoantibodies identify a subtype of «seronegative» myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002;82(9):1139–46.Scuderi F., Marino M., Colonna L. et al. Anti-p110 autoantibodies identify a subtype of «seronegative» myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002;82(9):1139–46.27. Sanders D. B., El-Salem K., Massey J. M. et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. In press 2003.Sanders D. B., El-Salem K., Massey J. M. et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. In press 2003.28. Farrugia M. E., Robson M. D., Clover L. et al. MRI and clinical studies of facial and bulbar involvement in MuSK antibodyassociated myasthenia gravis. Brain 2006;129:1481–92.Farrugia M. E., Robson M. D., Clover L. et al. MRI and clinical studies of facial and bulbar involvement in MuSK antibodyassociated myasthenia gravis. Brain 2006;129:1481–92.29. Oh S. J. Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol 2009;5(2):53–64.Oh S. J. Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol 2009;5(2):53–64.30. Pasnoor M., Wolfe G., Nations S. et al. Clinical findings in MuSK-antibody positive myasthenia gravis. Muscle Nerve 2010;41(3):370–4.Pasnoor M., Wolfe G., Nations S. et al. Clinical findings in MuSK-antibody positive myasthenia gravis. Muscle Nerve 2010;41(3):370–4.31. Oh S. J., Hatanakа Y., Hemmi S. et al. Repetitive nerve stimulation of facial muscles in MuSK antibody positive myasthenia gravis. Muscle Nerve 2006;33:500–4.Oh S. J., Hatanakа Y., Hemmi S. et al. Repetitive nerve stimulation of facial muscles in MuSK antibody positive myasthenia gravis. Muscle Nerve 2006;33:500–4.32. Evoli A., Tonali P. A., Padua L. et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304–11.Evoli A., Tonali P. A., Padua L. et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304–11.33. Vincent A., Bowen J., Newsom-Davis J. et al. Seronegative generalized myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003;2:99–106.Vincent A., Bowen J., Newsom-Davis J. et al. Seronegative generalized myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003;2:99–106.34. Maruyama K. Connectin, an elastic protein from myofibrils. J Biochem 1976; 80(2):405–7.Maruyama K. Connectin, an elastic protein from myofibrils. J Biochem 1976; 80(2):405–7.35. Wang K., McClure J., Tu A. Titin: major myofibrillar components of striated muscle. Proc Natl Acad Sci USA 1979;76(8):3698– 702.Wang K., McClure J., Tu A. Titin: major myofibrillar components of striated muscle. Proc Natl Acad Sci USA 1979;76(8):3698– 702.36. Maruyama K., Kimura S., Ohashi K., Kuwano Y. Connectin, an elastic protein of muscle. Identification of «titin» with connectin. J Biochem 1981;89(3):701–9.Maruyama K., Kimura S., Ohashi K., Kuwano Y. Connectin, an elastic protein of muscle. Identification of «titin» with connectin. J Biochem 1981;89(3):701–9.37. Strauss A. J.L., Seegal B. C., Hsu K. C. et al. Immunofluorescence demonstration of a muscle binding complement-fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med 1960;105:184–91.Strauss A. J.L., Seegal B. C., Hsu K. C. et al. Immunofluorescence demonstration of a muscle binding complement-fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med 1960;105:184–91.38. Beutner E. H., Witebsky E., Ricken D., Adler R. H. Studies on autoantibodies in myasthenia gravis. JAMA 1962;182:46–58.Beutner E. H., Witebsky E., Ricken D., Adler R. H. Studies on autoantibodies in myasthenia gravis. JAMA 1962;182:46–58.39. Aarli J. A., Stefansson K., Marton L. S., Wollmann R. L. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990;82(2):284–8.Aarli J. A., Stefansson K., Marton L. S., Wollmann R. L. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990;82(2):284–8.40. Gautel M., Lakey A., Barlow D. P. et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993;43:1581–5.Gautel M., Lakey A., Barlow D. P. et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993;43:1581–5.41. Mihovilovic M., Mai Y., Austin C., Roses A. D. Sera from myasthenia gravis patients recognize the PEVK domain of titin. Ann N Y Acad Sci 1998;841:534–7.Mihovilovic M., Mai Y., Austin C., Roses A. D. Sera from myasthenia gravis patients recognize the PEVK domain of titin. Ann N Y Acad Sci 1998;841:534–7.42. Skeie G. O., Freiburg A., Kolmerer B. et al. Titin transcripts in thymomas. J Autoimmun 1997;10(6):551–7.Skeie G. O., Freiburg A., Kolmerer B. et al. Titin transcripts in thymomas. J Autoimmun 1997;10(6):551–7.43. Romi F., Bo L., Skeie G. O. et al. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 2002;128(1–2):82–9.Romi F., Bo L., Skeie G. O. et al. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 2002;128(1–2):82–9.44. Yamamoto A. M., Gajdos P., Eymard B. et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001;58(6):885–90.Yamamoto A. M., Gajdos P., Eymard B. et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001;58(6):885–90.45. Voltz R., Albrich W., Hohlfeld R. et al. Anti-titin antibodies are not associated with a specific thymoma histology. J Neurol Neurosurg Psychiatry 2003;74(2):282.Voltz R., Albrich W., Hohlfeld R. et al. Anti-titin antibodies are not associated with a specific thymoma histology. J Neurol Neurosurg Psychiatry 2003;74(2):282.46. Санадзе А. Г., Сиднев Д. В., Давыдова Т. В. и др. Антитела к мышцам (антититиновые антитела) у больных с поздним началом миастении: клинические и электрофизиологические корреляции. Неврол журн 2003;8(Прил 1):23–6.Санадзе А. Г., Сиднев Д. В., Давыдова Т. В. и др. Антитела к мышцам (антититиновые антитела) у больных с поздним началом миастении: клинические и электрофизиологические корреляции. Неврол журн 2003;8(Прил 1):23–6.47. Romi F., Skeie G. O., Gilhus N. E., Aarli J. A. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005;62(3):442–6.Romi F., Skeie G. O., Gilhus N. E., Aarli J. A. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005;62(3):442–6.48. Сиднев Д. В., Санадзе А. Г., Щербакова Н. И. и др. Антитела к мышцам (антититиновые антитела) в диагностике миастении, сочетающейся с тимомой. Неврол журн 2003; 8(Прил 1):21–3.Сиднев Д. В., Санадзе А. Г., Щербакова Н. И. и др. Антитела к мышцам (антититиновые антитела) в диагностике миастении, сочетающейся с тимомой. Неврол журн 2003; 8(Прил 1):21–3.49. Romi F., Gilhus N. E., Varhaug J. E. et al. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 2003;10(6):701–6.Romi F., Gilhus N. E., Varhaug J. E. et al. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 2003;10(6):701–6.50. McPherson P.S., Campbell K. P. The ryanodine receptor / Ca2+ release channel. J Biol Chem 1993;268(19):765–8.McPherson P.S., Campbell K. P. The ryanodine receptor / Ca2+ release channel. J Biol Chem 1993;268(19):765–8.51. Bennett D. L., Cheek T. R., Berridge M. J. et al. Expression and function of ryanodine receptors in non-excitable cells. J Biol Chem 1996;11:6356–62.Bennett D. L., Cheek T. R., Berridge M. J. et al. Expression and function of ryanodine receptors in non-excitable cells. J Biol Chem 1996;11:6356–62.52. Mygland A., Tysnes O. B., Matre R. et al. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992;32(4):589–91.Mygland A., Tysnes O. B., Matre R. et al. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992;32(4):589–91.53. Romi F., Skeie G. O., Vedeler C. et al. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J Neuroimmunol 2000;111 (1–2):169–76.Romi F., Skeie G. O., Vedeler C. et al. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J Neuroimmunol 2000;111 (1–2):169–76.54. Skeie G. O., Mygland A., Treves S. et al. Ryanodine receptor antibodies in myasthenia gravis: epitopemapping and effect on calcium release in vitro. Muscle and Nerve 2003;27(1): 81–9.Skeie G. O., Mygland A., Treves S. et al. Ryanodine receptor antibodies in myasthenia gravis: epitopemapping and effect on calcium release in vitro. Muscle and Nerve 2003;27(1): 81–9.55. Mygland A., Tysnes O. B., Matre R. et al. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity 1994;17(4):327–31.Mygland A., Tysnes O. B., Matre R. et al. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity 1994;17(4):327–31.56. Imai T., Tsuda E., Hozuki T. et al. Contribution of anti-ryanodine receptor antibody to impairment of excitationcontraction coupling in myasthenia gravis. Clin Neurophysiol 2012;123(6): 1242–7.Imai T., Tsuda E., Hozuki T. et al. Contribution of anti-ryanodine receptor antibody to impairment of excitationcontraction coupling in myasthenia gravis. Clin Neurophysiol 2012;123(6): 1242–7.57. Mygland A., Kuwajima G., Mikoshiba K. et al. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995;62(1):79–83.Mygland A., Kuwajima G., Mikoshiba K. et al. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995;62(1):79–83.58. Romi F., Aarli J. A., Gilhus N. E. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 2007;14(6):617–20.Romi F., Aarli J. A., Gilhus N. E. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 2007;14(6):617–20.59. Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis 2011;2011:474–512.Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis 2011;2011:474–512.60. Nakata M., Kuwabara S., Kawaguchi N. et al. Is excitation-contraction coupling impaired in myasthenia gravis? Clin Neurophysiol 2007 May;118(5):1144–8.Nakata M., Kuwabara S., Kawaguchi N. et al. Is excitation-contraction coupling impaired in myasthenia gravis? Clin Neurophysiol 2007 May;118(5):1144–8.61. Bartoccioni E., Scuderi F., Minicuci G. M. et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006; 67(3):505–7.Bartoccioni E., Scuderi F., Minicuci G. M. et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006; 67(3):505–7.